Loading
A US law that lets certain hospitals buy outpatient drugs, including cancer drugs, at deep discounts. Controversial because hospitals may bill insurers full price.
United States, federal statute. Section 340B of the Public Health Service Act was created by the Veterans Health Care Act of 1992 (Public Law 102-585) and is administered by the Health Resources and Services Administration. Primary text: the HRSA 340B pages link the statute and guidance.
Enacted 1992; covered entities (disproportionate-share hospitals, federally qualified health centres) receive manufacturer discounts of 25-50%. It shapes where oncology infusions happen (hospital outpatient vs community practice), fuels hospital acquisition of oncology practices, and is under litigation and legislative pressure over contract pharmacies and rebate models.
Showing the technology this term belongs to: Community oncology and site networks.
Shares Oncology drug pricing and price transparency, Inflation Reduction Act 2022: Medicare drug price negotiation, Health technology assessment (HTA), reimbursement and QALYs, Financial toxicity.
Shares Pay a flat fee for giving a Part B drug instead of 6% of its price, Biologics Price Competition and Innovation Act 2010, Oncology drug pricing and price transparency, Hatch-Waxman Act 1984.
Shares Medicare coverage with evidence development, Health technology assessment (HTA), reimbursement and QALYs, Financial toxicity.
Shares Oncology drug pricing and price transparency, Financial toxicity.
Shares Biologics Price Competition and Innovation Act 2010, Hatch-Waxman Act 1984, Inflation Reduction Act 2022: Medicare drug price negotiation.
Shares Medicare coverage with evidence development, Health technology assessment (HTA), reimbursement and QALYs.
Shares Biologics Price Competition and Innovation Act 2010, Hatch-Waxman Act 1984.
Shares Oncology drug pricing and price transparency, Financial toxicity.